Reports Q4 revenue $6.54M, consensus $3.26M .Cash, cash equivalents, and marketable securities as of December 31, 2022, were $437.4M, compared to $478.5M as of September 30, 2022, and $619.9M as of December 31, 2021. The company expects that its existing cash, cash equivalents and marketable securities will fund operating expenses and capital expenditures into 2025.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EDIT:
- Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
- Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
- Editas Medicine initiated with an Overweight at Cantor Fitzgerald
- Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
- Shoreline to acquire Editas’ iNK cell franchise, related gene editing tech
